How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.

Slides:



Advertisements
Similar presentations
ETHICS AS CULTURE KEY ELEMENTS Stage One (primary) – Key Elements of a Culture of Ethics Appoint an ethics program manager to oversee your ethics-related.
Advertisements

Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
Environmental Management System (EMS)
Contractor Code of Business Ethics and Conduct Laura K. Kennedy Senior Vice President, Ethics and Compliance SAIC.
Contractor Assurance System AC Overview October 13, 2009.
ISO Culture SHOQ Quiz 1. This program must be run in MS PowerPoint and requires sound. 2. Click “View” and then “Slide Show”. 3. Click “Continue”
Contractor Safety Management
Presented by MUHAMMAD YAHYA AHMAD College of Education and Allied Program PCU, Manila.
18- 1 © 2006 The McGraw-Hill Companies, Inc., All Rights Reserved. Chapter 18 Integrated Audits of Internal Control (For Public Companies Under Sarbanes-Oxley.
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October Washington, D.C. David Davidovic,
Vendor Risk: Effective Management is Essential
Internal Auditing and Outsourcing
Key changes and transition process
What is Business Analysis Planning & Monitoring?
Protocol Complexity as a Factor in Vendor Management Compliance Risk
Audits & Assessments: What are the Differences and How Do We Learn from the Results? Brown Bag March 12, 2009 Sal Rubano – Director, Office of the Vice.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
ISO 14001:2004, Environmental Management System
1 DOE IMPLEMENTATION WORKSHOP ASSESSING MY EMS Steven R. Woodbury
Chapter 7 Auditing Internal Control over Financial Reporting McGraw-Hill/Irwin ©2008 The McGraw-Hill Companies, All Rights Reserved.
Clinical Trials in the Age of Personalized Cancer Medicine: The Evolution of a More Efficient, Patient Focused Clinical Research System Session Chair:
The views expressed in this presentation do not necessarily reflect those of the Federal Reserve Bank of New York or the Federal Reserve System Association.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
Georgia Institute of Technology CS 4320 Fall 2003.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
Integrating Compliance with Business: Developing and Implementing the Tysabri Risk Map Reintroduction of a Breakthrough Medical Product November 09, 2006.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin 7-1 Chapter Seven Auditing Internal Control over Financial Reporting.
Guidance Training (F520) §483.75(o) Quality Assessment and Assurance.
Office of Human Research Protection Georgia Health Sciences University.
Bayesian approach to equivalence study of medical device 1 1.
Lecture 5 Control and AIS Copyright © 2012 Pearson Education 7-1.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.
Draft White Paper “Protocol Deviations”
GCP (GOOD CLINICAL PRACTISE)
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Presenter Title Organization
Software Quality Control and Quality Assurance: Introduction
Track 11 Symposium 27 June :30 – 3:00 PM
Perspective on GCP Warning Letters
Implementing a Successful Corrective and Preventative Action Program
Molly Butler Auditor II Quality Associates, Inc.
Interactive Session: Presentation of Scenarios and Q&A
Introduction to Quality Risk Management in GCP
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
FirstPoint and FirstDoc Application of the DIA EDM Reference Model
Presenter Name Title Organization.
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
Presenter Name Title Organization.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
Quality Assurance in Clinical Trials
Presentation transcript:

How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers Squibb

Agenda Scope Audit approaches Audit of the vendor quality system Examples of audit findings

3 Scope Companies increase the level of outsourcing Outsourced aspects include –Study management –Study site monitoring –Central laboratories / bio imaging –IVRS systems –Data management –Safety data processing How to ensure adequate audit coverage?

4 Audit approaches Audit a sample of selected investigator sites –Pro : systems are seen in operation –Con : what to conclude if one site is good and the other is not? Audit the quality system at the vendor –Pro : can assess the processes that are established to ensure quality –Con : avoid that assessment is only based on theory Audit the CRO oversight process at the sponsor –Selection process, contracts, task lists –Important to assess systems put in place for communication and oversight

5 The audit approach ? A combination of all approaches Start with site audits to build your audit hypothesis Focus on integration of quality systems Focus on operational interfaces Determine best timing of the audit

6 6 Audit of Quality System DOACT DOACTDOACT Sponsor oversight Services by vendor Investigator Auditing CHECK PLAN

7 Audit of Vendor Quality System Audit the processes to detect failures What to assess for a monitoring vendor? –Monitor selection, geographical coverage, turnover and handover –Monitor training and SOPs –Monitoring contract, plan and other guidance –Early process controls –Oversight of other subcontractor performance How? –Investigator site audits : at least 3 sites –Vendor system audit

8 Audit of Vendor Quality System Audit the processes to correct failures What to assess for a monitoring vendor? –Monitoring reports –Issue identification and actions taken, escalation –Communication to sponsor –Systems to react to increased needs for monitoring How? –Vendor system audit

9 Audit of Vendor Quality System Audit the processes to prevent failures What to assess for a monitoring vendor? –Audit plans –Audit findings tracking and trending –Issue tracking and trending –Mechanisms to communicate issues with other vendors –Process improvement systems How? –Vendor system audit

10 Audit of Vendor Quality System Audit the process for issue management What? –Definition and understanding of Significant protocol deviations Serious breach Serious and or persistent non-compliance Fraud –Ways to detect issues: Have quality metrics Assess facts

11 Audit of Vendor Quality System Audit the process for issue management (2) What? –Who is informed / consulted –Process to react Joint directed audit Action plan with commitments Close follow-up –Responsibilities When is sponsor notified? Who is involved in the decision?

12 Case 1 : vendors requiring interaction Case description : a global vendor was contracted for study management and other vendors for monitoring of the sites Deficiencies in the QM system: –Monitoring tools were not shared –Monitoring systems do not connect Lessons learned : verify that robust processes are in place to detect non-compliance

13 Case 2 : vendor to provide oversight of another vendor Case description : a vendor responsible for study management was asked to track images for central evaluation by speciality vendor Deficiencies in the QM system: –No training of site staff, performing tests, was provided for –No feedback on early process control was returned to the sites Lessons learned : verify that robust processes are in place to prevent non-compliance

14 Case 3 : esoteric lab Case description : a university lab was contracted to provide evaluation of the primary efficacy parameter Deficiencies in the QM system: –Methodologies not standardised across labs –Procedures not specific enough –Absence of software validation Lessons learned : verify that processes (SOPs, validation) are in place to ensure standardised approaches

15 Case 4 :issue management and sponsor oversight Case description : site monitoring was outsourced Deficiencies in the QM system: –All protocol deviations were documented, reported, but no actions were taken –Vendor detected quality issues, sponsor decided on continuation of enrolment Lessons learned : verify that processes allow those that monitor the quality can make the appropriate decisions

16 Conclusions Sponsor may delegate responsibilities, but stays ultimately responsible. Role of sponsor to be clarified. Situation complicates as the number of partners involved increases. Sponsor should be confident in quality control and quality assurance implemented by the vendor. Important is not to only identify what goes wrong, but to act appropriately in alignment between vendor and sponsor.

17 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.